FDA Clears Lerodalcibep-Liga Autoinjector, Widens LDL-C Indication

The FDA has approved an autoinjector version of lerodalcibep-liga (Lerochol; Lib Theraprutics),¹ the once-monthly, third-generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor first approved for hypercholesterolemia (HeFH) in December 2025,² along with a label update that links the drug’s low-density lipoprotein cholesterol (LDL-C)–lowering ability to reduced cardiovascular risk. This new device will launch at the same $199 monthly cash price as the existing prefilled syringe, well below the roughly $14,000 annual list price payers faced when the first PCSK9 inhibitors launched in 2015.³

Lerodalcibep-liga’s December approval was for adjunctive treatment alongside diet and exercise for adults with HeFH, based on data from the phase 3 LIBerate clinical trial (NCT04797104).² The analysis saw more than 2900 enrollees and demonstrated sustained LDL-C reductions of 60% or greater in patients with, or at high risk for cardiovascular disease, and reductions of 59% and above in patients with HeFH and severely elevated LDL-C.

Label Changes With This Approval

The FDA authorized a single-use, pressure-activated autoinjector that delivers the same 300-mg/1.2-mL monthly dose as the prefilled syringe, which remains available as an administrative option.¹ This autoinjector is designed to complete dosing in seconds and requires no refrigeration, preserving lerodalcibep-liga’s room-temperature stability of up to 90 days—a feature Lib Therapeutics has positioned as a differentiator from earlier PCKS9 inhibitors that require cold storage.

Adverse events were consistent with those reported with the original approval.^1,2 Across trials in primary HeFH, the most common adverse reactions occurring more frequently vs placebo were nasopharyngitis, injection-site reactions, and peripheral edema. Injection-site reactions remained the most frequently cited reason for treatment discontinuation.¹

Alongside the device clearance, the FDA approved revised labeling stating that cardiovascular outcomes trials have shown LDL-C reduction lowers the risk of major adverse CV events in adults treated with statins or with monoclonal antibody PCSK9 inhibitors added to statin therapy. Evan Stein, MD, PhD, founder, CEO, and chief scientific officer of Lib Therapeutics, characterized the change as an FDA acknowledgement of nearly 40 years of evidence linking LDL-C lowering to reduced CV events.

“These studies have resulted in worldwide consensus and alignment of guidelines on new lower targets, and greater additional reductions in LDL-C, for the millions of patients who cannot reach guideline-directed LDL-C goals on maximally tolerated statin therapy,” Stein said in a statement. “The challenge now, with this newest class of very effective LDL-C lowering agents, is how to make them simple and affordable enough for patients, who must maintain them for what is life-long treatment. Lerochol was designed with a patient perspective in mind to achieve exactly that: a robust and sustained LDL-C reduction from a single, small monthly injection that patients self-administer, with room temperature storage of up to 90 days and now in a modern autoinjector device.”

What Does the $199 Price Mean for Managed Care?

The pricing context is notable against the backdrop of PCSK9 inhibitors’ rocky access history. When alirocumab and evolocumab launched in 2015, their exorbitant pricetag prompted payers and pharmacy benefits managers to impose strict prior authorization protocols.² A 2015 Institute for Clinical and Economic Review draft benchmark concluded those medications would need to fall to $2177 annually, an 85% discount, to meet standard cost-effectiveness thresholds.⁴ At $199/month, lerodalcibep-liga’s direct-to-patient cash price of $2388 per year sits close to that value-based benchmark.

Lib Therapeutics said insurance coverage is expected to expand gradually through 2027, and it plans further outreach to payers, clinicians, and patient advocacy groups to support access.¹ The autoinjector is expected to be available in the US by January 2027, and the company has submitted a marketing authorization application to the European Medicines Agency, with a decision expected sometime before the end of this year, as well as a biologics license application to China, with potential approval in 2027.

References

1. U.S. Food and Drug Administration approves an autoinjector version of Lerochol (lerodalcibep-liga) and updated indication. News release. BusinessWire. August 17, 2026. Accessed August 17, 2026. https://www.businesswire.com/news/home/20260817106971/en/U.S.-Food-and-Drug-Administration-Approves-an-Autoinjector-Version-of-LEROCHOL-lerodalcibep-liga-and-Updated-Indication
2. Klein H. FDA approves once-monthly PCSK9 injection for LDL-C reduction. AJMC^®. December 15, 2025. Accessed August 17, 2026. https://www.ajmc.com/view/fda-approves-once-monthly-pcsk9-injection-for-ldl-c-reduction
3. Caffrey M. For now, PBMs just say not to high-cost PCKS9 inhibitors. AJMC. September 18, 2015. Accessed August 17, 2026. https://www.ajmc.com/view/for-now-pbms--just-say-no-to--high-cost-pcsk9--inhibitors
4. Joszt L. PCSK9 inhibitors should cost 85% less, ICER reports. AJMC. September 10, 2015. Accessed August 17, 2026. https://www.ajmc.com/view/pcsk9-inhibitors-should-cost-85-less-icer-reports